These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 2565233)

  • 21. Cardiovascular actions of xamoterol (ICI 118,587) in anaesthetized cats, rats, and guinea pigs.
    Mian MA; Malta E; Raper C
    J Cardiovasc Pharmacol; 1986; 8(2):314-23. PubMed ID: 2422470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The electrophysiological effects of intravenous xamoterol in man.
    Bowes RJ; Gautam PC; Graham DR; Harley A
    Eur J Clin Pharmacol; 1986; 29(6):731-4. PubMed ID: 2872057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hemodynamic actions of prenalterol in left ventricular failure.
    Awan NA; Evenson MK; Needham KE; Mason DT
    Acta Med Scand Suppl; 1982; 659():251-61. PubMed ID: 6127893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of dobutamine and corwin, a beta 1-adrenergic partial agonist, in experimental left ventricular failure.
    Vik-Mo H; Yasay G; Maroko PR; Ribeiro LG
    J Cardiovasc Pharmacol; 1985; 7(4):784-90. PubMed ID: 2410722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of xamoterol on myocardial energetics in man.
    Sakai O; Fujita M; Sasayama S; Asanoi H; Nakajima H; Yokawa S
    Jpn Circ J; 1988 Feb; 52(2):149-54. PubMed ID: 2896256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
    Watanabe K; Hirokawa Y; Shibata A
    J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute haemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol at rest and during supine exercise in patients with left ventricular dysfunction due to ischaemic heart disease: a double-blind randomized trial.
    de Feyter PJ; Serruys PW
    Eur Heart J; 1990 Apr; 11 Suppl A():48-9. PubMed ID: 1971590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow.
    Leier CV; Patrick TJ; Hermiller J; Pacht KD; Huss P; Magorien RD; Unverferth DV
    Am Heart J; 1984 Dec; 108(6):1461-8. PubMed ID: 6507242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study.
    Sorensen EV; Sterndorff B; Andersen MF; Faergeman O
    Cardiovasc Drugs Ther; 1989 Apr; 3(2):203-9. PubMed ID: 2577283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
    Heng MK
    Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodynamic effects of ICI 118.587 (Corwin) in patients with mild cardiac failure after myocardial infarction.
    Svensson G; Rehnqvist N; Sjögren A; Erhardt L
    J Cardiovasc Pharmacol; 1985; 7(1):97-101. PubMed ID: 2580158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
    Pouleur H; Hanet C; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):82S-83S. PubMed ID: 2572263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.
    Sørensen EV; Faergeman O; Day MA; Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):86S-88S. PubMed ID: 2572265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses.
    Kukin ML; Kalman J; Mannino MM; Buchholz-Varley C; Ocampo O
    Heart; 1997 Nov; 78(5):444-9. PubMed ID: 9415001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xamoterol monotherapy in heart failure. The European 'Corwin' Group.
    Timewell RM; Stark RD; Marlow HF
    Eur Heart J; 1990 Apr; 11 Suppl A():62-4. PubMed ID: 1971596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic effects of intravenous diltiazem with impaired left ventricular function.
    Materne P; Legrand V; Vandormael M; Collignon P; Kulbertus HE
    Am J Cardiol; 1984 Oct; 54(7):733-7. PubMed ID: 6486022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.
    Rubin SA; Tabak L
    J Am Coll Cardiol; 1985 Jun; 5(6):1422-7. PubMed ID: 3158690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure.
    Pelliccia F; Borghi A; Ruggeri A; Cianfrocca C; Morgagni GL; Bugiardini R
    Clin Cardiol; 1993 Aug; 16(8):607-12. PubMed ID: 8370193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.